Glenn T. Stebbins, PhD, is a Professor Emeritus in the Movement Disorders Section of the Department of Neurological Sciences at Rush University Medical Center, Chicago, Illinois. His main research interest is the construction and validation of clinical outcome assessments for use in movement disorders which has resulted in the development of over 15 rating scales including such standard assessments as the Movement Disorder Society sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and the Unified Dyskinesia Rating Scale (UDysRS). He served as the Co-Director of the MDS Clinical Outcome Assessment program overseeing the development and implementation of multiple rating scales. Dr. Stebbins serves as advisor to the MJFF, CHDI Foundation, Critical Path for Parkinson's Consortium, Huntington's Disease Regulatory Science Consortium, Huntington Study Group and multiple industry partners. He has lectured internationally and is the author or co-author of more that 300 peer-reviewed articles, reviews, books, book chapters, and edited volumes.
Associated Grants
-
Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease
2012
-
-
Pilot Assessment of the Effect of Optimism and Expectation on Dyskinesia Rating Scales in Parkinson's Disease Subjects Randomized to Placebo or Amantadine
2009
-